Cargando...
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Talimogene laherparepvec is a first-in-class intralesional oncolytic immunotherapy. In a recent Phase III trial (OPTiM), talimogene laherparepvec significantly improved durable response rate compared with subcutaneous granulocyte–macrophage colony-stimulating factor (GM-CSF). Overall response rate w...
Guardado en:
| Publicado en: | Cancer Immunol Immunother |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer Berlin Heidelberg
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5445176/ https://ncbi.nlm.nih.gov/pubmed/28238174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-017-1967-1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|